BRPI0813218A2 - Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. - Google Patents
Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.Info
- Publication number
- BRPI0813218A2 BRPI0813218A2 BRPI0813218-6A2A BRPI0813218A BRPI0813218A2 BR PI0813218 A2 BRPI0813218 A2 BR PI0813218A2 BR PI0813218 A BRPI0813218 A BR PI0813218A BR PI0813218 A2 BRPI0813218 A2 BR PI0813218A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- contain
- pharmaceutical composition
- active principle
- aza
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical class C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 abstract 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007052598 | 2007-07-03 | ||
| PCT/IB2008/052656 WO2009004584A1 (en) | 2007-07-03 | 2008-07-02 | 3-aza-bicyclo[3.3.0]octane compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0813218A2 true BRPI0813218A2 (pt) | 2014-12-23 |
Family
ID=39863067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0813218-6A2A BRPI0813218A2 (pt) | 2007-07-03 | 2008-07-02 | Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8106215B2 (pt) |
| EP (1) | EP2164847B1 (pt) |
| JP (1) | JP2010531871A (pt) |
| KR (1) | KR20100041805A (pt) |
| CN (1) | CN101730696B (pt) |
| AT (1) | ATE524466T1 (pt) |
| AU (1) | AU2008272449A1 (pt) |
| BR (1) | BRPI0813218A2 (pt) |
| CA (1) | CA2691373A1 (pt) |
| ES (1) | ES2371514T3 (pt) |
| PL (1) | PL2164847T3 (pt) |
| WO (1) | WO2009004584A1 (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200823227A (en) * | 2006-09-29 | 2008-06-01 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
| WO2008065626A2 (en) | 2006-12-01 | 2008-06-05 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors |
| CL2007003827A1 (es) | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
| CL2008000836A1 (es) * | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| EP2150115B1 (en) | 2007-05-23 | 2013-09-18 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| US8288411B2 (en) * | 2007-09-24 | 2012-10-16 | Actelion Pharmaceuticals Ltd. | Pyrrolidines and piperidines as orexin receptor antagonists |
| CN101965343A (zh) * | 2008-02-21 | 2011-02-02 | 埃科特莱茵药品有限公司 | 2-氮杂-双环[2.2.1]庚烷衍生物 |
| US20110039857A1 (en) * | 2008-04-30 | 2011-02-17 | Hamed Aissaoui | Piperidine and pyroolidine compounds |
| KR20110071004A (ko) * | 2008-10-14 | 2011-06-27 | 액테리온 파마슈티칼 리미티드 | 페네틸아미드 유도체 및 이의 헤테로시클릭 유사체 |
| RS54945B1 (sr) | 2009-10-23 | 2016-11-30 | Janssen Pharmaceutica Nv | Disupstituisani oktahidropirolo[3,4-c]piroli kao oreksin receptor modulatori |
| HK1204955A1 (zh) * | 2012-02-07 | 2015-12-11 | Eolas Therapeutics Inc. | 取代的脯氨酸/哌啶用作食慾素受體拮抗劑 |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| TWI570120B (zh) | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
| WO2014057435A1 (en) | 2012-10-10 | 2014-04-17 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives |
| WO2014141065A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
| ITMI20130706A1 (it) * | 2013-04-30 | 2014-10-31 | Dipharma Francis Srl | Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| UA119549C2 (uk) | 2013-12-03 | 2019-07-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ТА ЇЇ ЗАСТОСУВАННЯ ЯК АНТАГОНІСТА ОРЕКСИНОВОГО РЕЦЕПТОРА |
| HUE040555T2 (hu) | 2013-12-04 | 2019-03-28 | Idorsia Pharmaceuticals Ltd | Benzimidazol prolin származékok alkalmazása |
| US10221170B2 (en) | 2014-08-13 | 2019-03-05 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
| PL3414241T3 (pl) | 2016-02-12 | 2022-10-03 | Astrazeneca Ab | Piperydyny podstawione halo jako modulatory receptora oreksyny |
| DK3426251T3 (da) | 2016-03-10 | 2022-06-20 | Janssen Pharmaceutica Nv | Fremgangsmåder til behandling af depression under anvendelse af orexin-2-receptorantagonister |
| KR102611212B1 (ko) | 2016-04-19 | 2023-12-07 | 삼성디스플레이 주식회사 | 액정 조성물 및 이를 포함하는 액정 표시 장치 |
| SG11202008113RA (en) | 2018-03-05 | 2020-09-29 | Arcus Biosciences Inc | Arginase inhibitors |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| JP2022534704A (ja) | 2019-06-04 | 2022-08-03 | ヘイガー バイオサイエンシズ，エルエルシー | オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 |
| WO2023218023A1 (en) | 2022-05-13 | 2023-11-16 | Idorsia Pharmaceuticals Ltd | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
| US12122770B1 (en) * | 2023-10-23 | 2024-10-22 | King Faisal University | 2-(benzo[d]oxazol-2-yl)-n'-(nicotinoyloxy)acetimidamide as an antimicrobial compound |
| WO2025224168A1 (en) | 2024-04-24 | 2025-10-30 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57139032A (en) | 1981-02-20 | 1982-08-27 | Takasago Corp | 2-(butan-2-on-3-yl)-5-methylphenol and perfumery composition containing the same |
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| EP0757692A1 (en) | 1994-04-29 | 1997-02-12 | PHARMACIA & UPJOHN COMPANY | Methanol derivatives for treatment of retroviral infections especially hiv infections |
| EP1289955B1 (en) * | 2000-06-16 | 2005-04-13 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| EP1353918B1 (en) | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| MXPA03010129A (es) | 2001-05-05 | 2004-03-10 | Smithkline Beecham Plc | N-aroilaminas-ciclicas. |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| ES2273083T3 (es) * | 2002-09-18 | 2007-05-01 | Glaxo Group Limited | N-aroilaminas ciclicas como antagonistas de los receptores de orexina. |
| CA2499128C (en) | 2002-09-25 | 2012-07-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| GB0225944D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| US7056817B2 (en) * | 2002-11-20 | 2006-06-06 | Intel Corporation | Forming a cap above a metal layer |
| BRPI0508771A (pt) | 2004-03-25 | 2007-08-14 | Memory Pharm Corp | indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos |
| AU2007285371A1 (en) * | 2006-08-15 | 2008-02-21 | Actelion Pharmaceuticals Ltd. | Azetidine compounds as orexin receptor antagonists |
| TW200823227A (en) | 2006-09-29 | 2008-06-01 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
| WO2008065626A2 (en) * | 2006-12-01 | 2008-06-05 | Actelion Pharmaceuticals Ltd | 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors |
| BRPI0814593A2 (pt) * | 2007-07-27 | 2015-01-20 | Actelion Pharmaceuticals Ltd | Composto, composição farmacêutica que o contém e uso do composto. |
-
2008
- 2008-07-02 CN CN2008800232482A patent/CN101730696B/zh not_active Expired - Fee Related
- 2008-07-02 US US12/667,193 patent/US8106215B2/en not_active Expired - Fee Related
- 2008-07-02 PL PL08763445T patent/PL2164847T3/pl unknown
- 2008-07-02 WO PCT/IB2008/052656 patent/WO2009004584A1/en not_active Ceased
- 2008-07-02 CA CA002691373A patent/CA2691373A1/en not_active Abandoned
- 2008-07-02 JP JP2010514232A patent/JP2010531871A/ja not_active Ceased
- 2008-07-02 KR KR1020107002315A patent/KR20100041805A/ko not_active Withdrawn
- 2008-07-02 BR BRPI0813218-6A2A patent/BRPI0813218A2/pt not_active IP Right Cessation
- 2008-07-02 EP EP08763445A patent/EP2164847B1/en not_active Not-in-force
- 2008-07-02 AT AT08763445T patent/ATE524466T1/de active
- 2008-07-02 ES ES08763445T patent/ES2371514T3/es active Active
- 2008-07-02 AU AU2008272449A patent/AU2008272449A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE524466T1 (de) | 2011-09-15 |
| US8106215B2 (en) | 2012-01-31 |
| KR20100041805A (ko) | 2010-04-22 |
| EP2164847A1 (en) | 2010-03-24 |
| ES2371514T3 (es) | 2012-01-04 |
| EP2164847B1 (en) | 2011-09-14 |
| AU2008272449A1 (en) | 2009-01-08 |
| RU2010103322A (ru) | 2011-08-10 |
| CA2691373A1 (en) | 2009-01-08 |
| US20100184808A1 (en) | 2010-07-22 |
| PL2164847T3 (pl) | 2012-02-29 |
| CN101730696A (zh) | 2010-06-09 |
| WO2009004584A1 (en) | 2009-01-08 |
| CN101730696B (zh) | 2013-01-09 |
| JP2010531871A (ja) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0813218A2 (pt) | Composto, composição farmacêutica que o contém como princípio ativo e uso do composto. | |
| ATE483707T1 (de) | 2-cyclopropylthiazolderivate | |
| BRPI0605921B8 (pt) | compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
| DOP2009000293A (es) | Derivados de piperidina utiles como antagonistas receptores de orexina. | |
| ATE493386T1 (de) | Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate | |
| MX2009009690A (es) | Derivados de tiazolidina como antagonistas del receptor de orexina. | |
| MX2010001575A (es) | Derivados de 1,2-diamido-etileno como antagonistas de orexina. | |
| ATE500250T1 (de) | Azetidinverbindungen als orexin-rezeptor- antagonisten | |
| BRPI0910182B8 (pt) | composto de fórmula (i), composição farmacêutica e uso de um composto | |
| DOP2011000176A (es) | Compuestos organicos | |
| HN2008001530A (es) | Compuestos de amino pirimidina 2,6- sustituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| DE602007012072D1 (de) | Orantagonisten | |
| ATE458740T1 (de) | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten | |
| HN2010001059A (es) | Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes. | |
| ECSP088265A (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| BRPI0821004A8 (pt) | Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste | |
| DE602005014382D1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren | |
| PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
| MX2010008713A (es) | Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii. | |
| CL2011000784A1 (es) | Compuestos derivados de 7-h-pirazoli[3,4-e]-diasepina-6(5h)-ona sustituidos; procedimiento de preparacion; composicion farmaceutica, utiles como agentes antibacteriales. | |
| CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
| CR10603A (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| NI201100015A (es) | Compuestos novedosos activos como antagonistas de receptor muscarínico. | |
| UY29440A1 (es) | Nuevos compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |